Literature DB >> 10898445

Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study.

Y Mori1, M Nakazawa, H Tomimatsu, K Momma.   

Abstract

OBJECTIVES: This study examined whether long-term therapy with an angiotensin-converting enzyme (ACE) inhibitor reduces excessive increases in left ventricular (LV) mass as well as volume in growing children with aortic regurgitation or mitral regurgitation.
BACKGROUND: The ACE inhibitor reduces volume overload and LV hypertrophy in adults with aortic or mitral regurgitation.
METHODS: This study included 24 patients whose ages ranged from 0.3 to 16 years at entry to the study. On echocardiography, we measured LV size, systolic function and mass. After obtaining baseline data, patients were allocated into two groups. Twelve patients were given an ACE inhibitor (ACE inhibitor group), and 12 patients were not (control group). Echo parameters were again assessed after an average 3.4 years of follow-up.
RESULTS: Left ventricular parameters at baseline in the two groups were similar. The Z value of LV end-diastolic dimensions decreased from +0.82 +/- 0.55 to +0.57 +/- 0.58 in the ACE inhibitor group, whereas it increased from +0.73 +/- 0.85 to +1.14 +/- 1.04 in the control group (mean change -0.25 +/- 0.33 for the ACE inhibitor group vs. +0.42 +/- 0.48 for the control group, p = 0.0007). The mass normalized to growth also reduced from 221 +/- 93% to 149 +/- 44% of normal in the ACE inhibitor group and increased from 167 +/- 46% to 204 +/-59% of normal in the control group (mean change -72 +/- 89% of normal for the ACE inhibitor group vs. +37 +/- 35% of normal for the control group, p = 0.0007).
CONCLUSIONS: Long-term treatment with ACE inhibitors is effective in reducing not only LV volume overload but also LV hypertrophy in the hearts of growing children with LV volume overload.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898445     DOI: 10.1016/s0735-1097(00)00673-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  The cause of B-type natriuretic peptide elevation and the dose-dependent effect of angiotensin-converting enzyme inhibitor on patients late after tetralogy of Fallot repair.

Authors:  Takuo Furukawa; Tomoaki Murakami; Michihiko Ueno; Atsuhito Takeda; Satoshi Yakuwa; Hirokuni Yamazawa
Journal:  Pediatr Cardiol       Date:  2011-09-30       Impact factor: 1.655

2.  Effectiveness of angiotensin-converting enzyme inhibitors in pediatric patients with mid to severe aortic valve regurgitation.

Authors:  Fabian Gisler; Walter Knirsch; Paul Harpes; Urs Bauersfeld
Journal:  Pediatr Cardiol       Date:  2008-04-10       Impact factor: 1.655

3.  Enalapril in infants with single ventricle: results of a multicenter randomized trial.

Authors:  Daphne T Hsu; Victor Zak; Lynn Mahony; Lynn A Sleeper; Andrew M Atz; Jami C Levine; Piers C Barker; Chitra Ravishankar; Brian W McCrindle; Richard V Williams; Karen Altmann; Nancy S Ghanayem; Renee Margossian; Wendy K Chung; William L Border; Gail D Pearson; Mario P Stylianou; Seema Mital
Journal:  Circulation       Date:  2010-07-12       Impact factor: 29.690

4.  Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle.

Authors:  Seema Mital; Wendy K Chung; Steven D Colan; Lynn A Sleeper; Cedric Manlhiot; Cammon B Arrington; James F Cnota; Eric M Graham; Michael E Mitchell; Elizabeth Goldmuntz; Jennifer S Li; Jami C Levine; Teresa M Lee; Renee Margossian; Daphne T Hsu
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

Review 5.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

Review 6.  Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy.

Authors:  Stefan Rupp; Christian Jux
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 7.  Are vasodilators still indicated in the treatment of severe aortic regurgitation?

Authors:  Jocelyn Inamo; Maurice Enriquez-Sarano
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

8.  Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle.

Authors:  Daphne T Hsu; Seema Mital; Chitra Ravishankar; Renee Margossian; Jennifer S Li; Lynn A Sleeper; Richard V Williams; Jami C Levine; Brian W McCrindle; Andrew M Atz; Darlene Servedio; Lynn Mahony
Journal:  Am Heart J       Date:  2009-01       Impact factor: 4.749

Review 9.  Timing of aortic valve intervention in pediatric chronic aortic insufficiency.

Authors:  Justin T Tretter; Alan Langsner
Journal:  Pediatr Cardiol       Date:  2014-09-02       Impact factor: 1.655

Review 10.  ACE inhibitors in pediatric patients with heart failure.

Authors:  Kazuo Momma
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.